CD47 and neoplasm: In immunotherapy, the combination of GD2 monoclonal antibody (mAb), chemotherapy regimen and autologous NK cells or the combination of anti-GD2 antibody and other antibodies or CART, such as CD47 mAb, have been reported to improve the tumour immunosuppressive microenvironment and enhance the therapeutic effect [15, 16].